Patient demographics and baseline disease characteristics
| . | LDAC . | LDAC + volasertib . |
|---|---|---|
| No. of patients | 45 | 42 |
| Age (y), median (range) | 76 (57-86) | 75 (65-87) |
| No. of patients >75 y, n (%) | 23 (51) | 19 (45) |
| Gender (male), n (%) | 25 (56) | 23 (55) |
| ECOG performance status, n (%) | ||
| 0 | 16 (36) | 10 (24) |
| 1 | 20 (44) | 23 (55) |
| 2 | 9 (20) | 9 (21) |
| WBC, 109/L, median (range) | 5.2 (1.0-98.2) | 6.0 (0.7-104.9) |
| BM blasts, %, median (range) | 41 (20-95) | 50 (10-93) |
| Secondary AML, n (%) | 29 (64) | 17 (41) |
| Preceding MDS | 16 | 11 |
| Preceding MPN | 7 | 3 |
| Prior therapy | 4 | 1 |
| Missing | 2 | 2 |
| Genetic group (ELN classification), n (%) | ||
| Favorable | 3/42 (7) | 1/36 (3) |
| Intermediate I/II | 25/42 (60) | 21/36 (58) |
| Adverse | 14/42 (33) | 14/36 (39) |
| Missing | 3 | 6 |
| Gene mutations, n (%) | ||
| NPM1 mutation | 7/40 (18) | 7/33 (21) |
| NPM1 results missing | 5 | 9 |
| FLT3-ITD | 6/39 (15) | 5/35 (14) |
| FLT3-ITD results missing | 6 | 7 |
| Wheatley risk group, n (%) | ||
| Good | 1 (2) | 0 (0) |
| Standard | 14 (31) | 12 (29) |
| Poor | 30 (67) | 30 (71) |
| . | LDAC . | LDAC + volasertib . |
|---|---|---|
| No. of patients | 45 | 42 |
| Age (y), median (range) | 76 (57-86) | 75 (65-87) |
| No. of patients >75 y, n (%) | 23 (51) | 19 (45) |
| Gender (male), n (%) | 25 (56) | 23 (55) |
| ECOG performance status, n (%) | ||
| 0 | 16 (36) | 10 (24) |
| 1 | 20 (44) | 23 (55) |
| 2 | 9 (20) | 9 (21) |
| WBC, 109/L, median (range) | 5.2 (1.0-98.2) | 6.0 (0.7-104.9) |
| BM blasts, %, median (range) | 41 (20-95) | 50 (10-93) |
| Secondary AML, n (%) | 29 (64) | 17 (41) |
| Preceding MDS | 16 | 11 |
| Preceding MPN | 7 | 3 |
| Prior therapy | 4 | 1 |
| Missing | 2 | 2 |
| Genetic group (ELN classification), n (%) | ||
| Favorable | 3/42 (7) | 1/36 (3) |
| Intermediate I/II | 25/42 (60) | 21/36 (58) |
| Adverse | 14/42 (33) | 14/36 (39) |
| Missing | 3 | 6 |
| Gene mutations, n (%) | ||
| NPM1 mutation | 7/40 (18) | 7/33 (21) |
| NPM1 results missing | 5 | 9 |
| FLT3-ITD | 6/39 (15) | 5/35 (14) |
| FLT3-ITD results missing | 6 | 7 |
| Wheatley risk group, n (%) | ||
| Good | 1 (2) | 0 (0) |
| Standard | 14 (31) | 12 (29) |
| Poor | 30 (67) | 30 (71) |
BM, bone marrow; ECOG, Eastern Cooperative Oncology Group; ITD, internal tandem duplication; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; WBC, white blood cell.